Data from CV outcome trials showed that SGLT2 inhibitors slow the progression of kidney function decline and reduce the risks of kidney outcomes in T2DM patients with preserved kidney function (Mosenzon et al. 2019; Neal et al. 2017a; Wiviott et al. 2018; Zinman et al. 2015a). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.